

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUPIN LTD. and LUPIN PHARMACEUTICALS INC.
Petitioners

v.

SENJU PHARMACEUTICAL CO., LTD.
Patent Owner

Inter Partes Review No.: Unassigned

**PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 8,927,606
UNDER 35 U.S.C. §§ 311-319 AND 37 C.F.R. §§ 42.1-.80, 42.100-.123**

Mail Stop **Patent Board**
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	OVERVIEW	1
III.	STANDING (37 C.F.R. § 42.104(a)); PROCEDURAL STATEMENTS	2
IV.	MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1)).....	2
V.	STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE (37 C.F.R. § 42.22(a)).....	4
VI.	CLAIM CONSTRUCTION	4
VII.	PERSON OF ORDINARY SKILL IN THE ART AND STATE OF THE ART.....	6
	A. Person of Ordinary Skill in the Art	6
	B. State of the Art	7
VIII.	IDENTIFICATION OF CHALLENGE AND RELIEF REQUESTED	11
	A. Ground 1: Claims 1-30 Are Unpatentable Under 35 U.S.C. § 103(a) over the '225 patent in view of EP '984	12
	1. Independent claims 1, 11, and 19	16
	2. Disease Indications (claims 2, 3, 13, 14, 20, and 21)	24
	3. Dosage Information (claim 10).....	26
	4. Stability (claims 12 and 26)	26
	5. Pharmacologically acceptable salts (claims 4, 7, 17, and 22)	27
	a. Quaternary Ammonium Salt (claims 7 and 17).....	27
	b. Sodium Salt (claims 4 and 22).....	28
	6. Concentration of Components (claims 5, 6, 8, 9, 15, 16, 18, 23, 24, 25, and 27)	29
	a. Bromfenac Concentration (claims 5, 6, 8, 9, 15, 16, 18, 23, 24, 25, and 27)	29
	b. Tyloxapol Concentration (claims 5, 15, and 23)	31
	c. Additional Components (claims 9, 18, and 25).....	31

7.	Preservative Efficacy Standard of EP-criteria B (claims 28 – 30)	34
B.	Ground 2: Claims 1-30 Are Unpatentable Under 35 U.S.C. § 103(a) over the '913 patent in view of the '225 patent	36
1.	Independent claims 1, 11, and 19	38
2.	Disease Indications (claims 2, 3, 13, 14, 20, and 21)	43
3.	Dosage Information (claim 10)	44
4.	Stability (claims 12 and 26)	45
5.	Pharmacologically acceptable salts (claims 4, 7, 17, and 22)	46
a.	Quaternary Ammonium Salt (claims 7 and 17).....	46
b.	Sodium Salt (claims 4 and 22).....	47
6.	Concentration of Components (claims 5, 6, 8, 9, 15, 16, 18, 23, 24, 25, and 27)	48
a.	Bromfenac Concentration (claims 5, 6, 8, 9, 15, 16, 18, 23, 24, 25, and 27)	48
b.	Tyloxapol Concentration (claims 5, 15, and 23)	50
c.	Additional Components (claims 9, 18, and 25).....	51
7.	Preservative Efficacy Standard of EP-criteria B (claims 28 – 30)	53
C.	Objective indicia of nonobviousness	55
1.	Any assertions of unexpected stability in the claimed formulations do not support patentability	56
2.	Other Objective Indicia.....	58
IX.	CONCLUSION.....	59

Petitioners' Exhibit List

<i>Exhibit #</i>	<i>Description</i>
1001	Sawa et al., U.S. Patent No. 8,669,290, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued March 11, 2014.
1002	Sawa et al., U.S. Patent No. 8,754,131, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued June 17, 2014.
1003	Sawa et al., U.S. Patent No. 8,871,813, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued October 28, 2014.
1004	Sawa et al., U.S. Patent No. 8,927,606, "Aqueous Liquid Preparation Containing 2-Amino-3-(4-Bromobenzoyl) Phenylacetic Acid," issued January 6, 2015.
1005	Declaration of Dr. Jayne Lawrence
1006	Hara, Y., "Bromfenac sodium hydrate," <i>Clinics & Drug Therapy</i> 19:1014-1015 (2002).
1007	Yanni et al., U.S. Patent No. 5,475,034, "Topically Administrable Compositions Containing 3-Benzoylphenylacetic Acid Derivatives for Treatment of Ophthalmic Inflammatory Disorders," issued December 12, 1995.
1008	FDA Approved "Xibrom™ (bromfenac ophthalmic solution, 0.09%) Product Label," ISTA Pharmaceuticals, Inc.
1009	FDA Approved "BROMDAY™ (bromfenac ophthalmic solution, 0.09%) Product Label," U.S. Approval March 24, 2005, ISTA Pharmaceuticals, Inc.

1010	Ogawa et al., U.S. Patent No. 4,910,225, "Locally Administrable Therapeutic Composition for Inflammatory Disease," issued March 20, 1990.
1011	Sallmann et al., U.S. Patent No. 6,107,343, "Ophthalmic And Aural Compositions Containing Diclofenac Potassium," issued August 22, 2000.
1012	Desai et al., U.S. Patent No. 5,603,929, "Preserved Ophthalmic Drug Compositions Containing Polymeric Quaternary Ammonium Compounds," issued February 18, 1997.
1013	Desai et al., U.S. Patent No. 5,558,876, "Topical Ophthalmic Acidic Drug Formulations," issued September 24, 1996.
1014	Fu et al., European Patent Application No. 88114804.3, "Preservative System for Ophthalmic Formulations," published as EP 0 306 984 A1 on March 15, 1989.
1015	Schott, H., "Comparing the Surface Chemical Properties and the Effect of Salts on the Cloud Point of a Conventional Nonionic Surfactant, Octoxynol 9 (Triton X-100), and of Its Oligomer, Tyloxapol (Triton WR-1339)," <i>Journal of Colloid and Interface Science</i> 205: 496-502 (1998).
1016	"Acular®" and "Azopt™," <i>Physician's Desk Reference</i> , 54:486-487, and 491-492 (2000).
1017	Doughty, M., "Medicines Update for optical practitioners - Part 11," <i>Optician</i> , 5853:223 (2002).
1018	FDA approved "ALREX™ (loteprednol etabonate ophthalmic suspension) 0.2% Product Label," U.S. Approval: 1998, Bausch & Lomb Pharmaceuticals.
1019	FDA approved "LOTEMAX™ (loteprednol etabonate ophthalmic suspension) 0.5% Product Label," U.S. Approval: 1998, Bausch & Lomb Pharmaceuticals.
1020	"Alomide®", <i>Physician's Desk Reference</i> , 50:469 (1996).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.